Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dyne Therapeutics, Inc. (Nasdaq: DYN) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Dyne is a clinical-stage biopharmaceutical company focused on genetically driven neuromuscular diseases, and its filings offer detailed insight into its programs, financing activities and risk disclosures.
Investors can review current reports on Form 8-K, where Dyne reports material events such as quarterly financial results, public offerings of common stock, loan and security agreements, regulatory designations for its product candidates and changes to its board of directors. For example, recent 8-K filings describe underwritten public offerings of DYN common stock, a term loan facility with Hercules Capital, Inc., Breakthrough Therapy Designation for DYNE-251, and director appointments.
Through Dyne’s registration statements and prospectus supplements referenced in its filings, users can track details of equity offerings made under its shelf registration on Form S-3. Filings also identify that DYN common stock is registered under Section 12(b) of the Exchange Act and listed on the Nasdaq Global Select Market.
On Stock Titan, these documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as financing terms, cash runway statements, clinical and regulatory milestones referenced in disclosure, and covenant structures in loan agreements. Users can follow new 8-Ks and other submissions as they are made available through EDGAR, and use the summarized content to orient themselves before consulting the full text of each filing.
Dyne Therapeutics’ Chief Financial Officer Erick Lucera received new equity awards. On February 12, 2026, Lucera was granted 65,000 restricted stock units, each representing one share of common stock, at a grant price of $0. These RSUs are scheduled to vest in equal quarterly installments over four years starting May 12, 2026.
On the same date, Lucera also received a stock option covering 105,000 shares of common stock with an exercise price of $16 per share. This option vests in equal monthly installments over four years through February 12, 2030. Following the RSU grant, Lucera directly beneficially owns 131,100 unvested RSUs.
Janus Henderson Group plc reported its beneficial ownership of common stock of Dyne Therapeutics Inc. as of December 31, 2025. Through its investment adviser subsidiaries managing client accounts, it may be deemed to beneficially own 13,887,722 Dyne Therapeutics shares, representing 8.5% of the class.
The Janus Henderson asset managers hold shared power to vote and dispose of these shares, with no sole voting or dispositive power. The economic benefits, including dividends and sale proceeds, belong to the underlying managed portfolios, and Janus Henderson disclaims ownership of those rights.
Dyne Therapeutics, Inc. reported that it expects to disclose cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025. The company noted that its fourth-quarter and full-year 2025 financial results are not yet finalized and this cash figure is a preliminary, unaudited management estimate that remains subject to completion of normal closing procedures.
The company also made available an investor presentation on January 12, 2026, covering its current operations, future plans and other business updates. The presentation was filed as Exhibit 99.1 and is incorporated by reference, while the cash update and presentation are furnished for information purposes and are not deemed filed under securities laws unless specifically incorporated in other documents.
T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting beneficial ownership of 17,540,089 shares of Dyne Therapeutics Inc. common stock, representing 10.7% of the class as of the event date. The firm has sole power to vote 17,517,597 of these shares and sole power to dispose of 17,540,089 shares, with no shared voting or dispositive power. T. Rowe Price classifies itself as an investment adviser and states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Dyne Therapeutics.
Dyne Therapeutics CEO and President, who is also a director, reported selling 2,662 shares of Common Stock on December 5, 2025 at a weighted average price of $20.72. The shares were automatically sold to satisfy tax withholding obligations tied to restricted stock units granted on December 4, 2024, under a restricted stock unit agreement that constitutes a binding contract consistent with the affirmative defense to liability under Rule 10b5-1, so the sale did not represent a discretionary trade.
After this transaction, the insider beneficially owns 196,877 shares directly, including 108,976 unvested RSUs, and 18,000 shares held in each of four trusts for the benefit of the reporting person’s children. The report notes that 2,662 shares were matchable under Section 16(b) with a prior purchase of 100,000 shares on July 14, 2025, and the reporting person has paid the issuer $31,111.88, representing the profit deemed realized on that short-swing transaction.
Dyne Therapeutics (DYN) furnished quarterly results. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and made it available as Exhibit 99.1.
The disclosure is furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically stated. The common stock trades on the Nasdaq Global Select Market under the symbol DYN.
Dyne Therapeutics (DYN) filed its Q3 2025 10‑Q, reporting higher cash and continued R&D investment. Cash and cash equivalents were $573.6 million, with marketable securities of $218.3 million. Total assets reached $867.1 million. The company posted a Q3 net loss of $108.0 million ($0.76 per share) on operating expenses of $113.9 million, driven by research and development of $97.2 million and general and administrative of $16.7 million.
To strengthen liquidity, Dyne completed a public offering for net proceeds of $215.8 million and sold $140.6 million via its at‑the‑market program year‑to‑date. It also drew $100.0 million under a term loan with Hercules, due July 1, 2030, bearing interest at the prime rate (floor 7.50%) plus 2.45%. Long‑term debt, net, was $99.1 million. Shares outstanding were 142.6 million at quarter‑end.
Program updates include FDA Breakthrough Therapy Designation for z‑basivarsen (DM1) and initiation of a registrational expansion cohort in ACHIEVE. For z‑rostudirsen (DMD), the DELIVER 20 mg/kg Q4W registrational expansion cohort completed enrollment, with data planned in December 2025. Subsequent to quarter‑end, Dyne committed at least $25.5 million through March 2027 under a CMO manufacturing agreement.
Dyne Therapeutics, Inc. (DYN) director Brian S. Posner received a stock option grant on 10/01/2025 for 70,000 shares with an exercise price of $12.50. The option is exercisable for underlying common stock and shows 70,000 shares beneficially owned following the grant, reported as direct ownership. The option vests over three years in equal monthly installments through 10/01/2028, giving the director continuing equity alignment over that period. The Form 4 was signed on 10/02/2025 by an attorney-in-fact on behalf of the reporting person.
Brian S. Posner filed an SEC Form 3 as an initial statement of beneficial ownership for Dyne Therapeutics, Inc. (DYN). The event date is 10/01/2025 and the filing reports direct beneficial ownership of 8,500 shares of the issuer's common stock. The form identifies Mr. Posner as a Director and was signed on behalf of the reporting person by Ron Caponigro, Attorney-in-Fact on 10/02/2025. The filing includes a listed address in Waltham, MA and references a Power of Attorney (Exhibit 24.1).
Dyne Therapeutics appointed Brian Posner as a Class III director, with his term running until the 2026 annual stockholders’ meeting and subject to standard continuation conditions. The Board determined he qualifies as an independent director under Nasdaq rules and he is not serving on any Board committees.
Upon election, Posner received a stock option for 70,000 shares at an exercise price of $12.50 per share, vesting in equal monthly installments over three years, with full acceleration upon a change in control. He will also receive $45,000 in annual cash Board fees, additional annual equity grants under the non-employee director program, and reimbursement of reasonable travel and out-of-pocket Board-related expenses.
The company states there are no arrangements, family relationships, or related-party transactions involving Posner that require disclosure, and he will enter into Dyne’s standard indemnification agreement for directors.